The AstraZeneca vaccine has faced scrutiny in recent months for its links to blood clots. But some good news relating to the vaccine has now emerged – a new study has shown it to be 97 percent effective against the Indian Covid variant, the strain currently causing concern in the UK. New research of nearly 3,300 people in India discovered only two hospitalizations with Covid. All of the people analyzed were vaccinated with the AstraZeneca jab, and they worked in healthcare.
The Indraprastha Apollo Hospital in Delhi published the study, finding a hospital admission rate of less than 1 per cent. Dr Anupam Sibal, group medical director, said: “Our study demonstrated that 97.38 per cent of those vaccinated were protected from an infection.”
The study comes after Health Secretary Matt Hancock sounded caution over the Indian variant of the virus currently spreading like wildfire among the young. Professor Adam Finn, from the University of Bristol and a member of the Joint Committee on Vaccination and Immunization (JCVI), was asked if the JCVI would look again at the recommendation that people under 40 should be offered non-AstraZeneca jabs if it means that it could speed up the rollout. When we expressed a preference for non-AstraZeneca vaccines for this age group it was done in a very provisional way on the basis of everything going absolutely right. And if the evidence shows that the risk benefit balance for people in their 30s is to be offered that vaccine then absolutely that recommendation will be changed.